August Health vs Bristol Myers Squibb
Side-by-side comparison of AI visibility scores, market position, and capabilities
Assisted living operations and care management platform built for modern senior living communities, replacing paper-based workflows with AI-assisted assessments and digital care planning.
About
August Health is a San Francisco, California-based senior care technology company building a modern cloud-native platform for assisted living and memory care communities. Founded in 2019 and having raised over $14 million from investors including a16z and others, August Health targets the large segment of senior living communities still operating on paper-based or legacy software workflows. The company's platform digitizes resident assessments, care planning, incident reporting, medication management, and family communication in a design-forward interface built for use by care staff on mobile devices.\n\nA key differentiator for August Health is its use of AI to assist care staff in completing state-required assessments and care plans. The platform can generate draft care plan language based on assessment responses, reducing the documentation burden on caregivers while improving consistency and completeness of clinical records. This AI-assisted documentation capability is particularly valuable in assisted living, where staffing challenges and high turnover make efficient documentation workflows critical to operational quality.\n\nAugust Health competes with established vendors like Yardi Senior Living and MatrixCare but targets smaller independent communities and regional groups that find legacy platforms overly complex and expensive for their needs. The company's modern UX, mobile-first design, and AI-assisted features position it as a next-generation alternative in a market where much of the installed base runs on software designed before smartphones existed. As the senior care sector faces mounting staffing pressure, technology that reduces administrative burden on direct care staff is increasingly valued by operators.
Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.
About
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.